Chronic Disease Management Market - By Disease Type, By Type, By End Use - Global Forecast, 2025 – 2034

Chronic Disease Management Market Size

The global chronic disease management market was valued at USD 6.2 billion in 2024. The market is expected to grow from USD 6.9 billion in 2025 to USD 18.8 billion in 2034 at a CAGR of 11.7%. The market growth is primarily driven due to the increasing incidence of chronic diseases such as diabetes, cardiovascular diseases (CVD), and hypertension that emphasizes the need for effective disease management solutions.
 

For instance, the International Diabetes Federation (IDF) Diabetes Atlas stated that globally in 2019, diabetes prevalence was estimated to be 9.3%. This is expected to rise to 10.2% by 2030 reaching 10.9% by 2045. This illustrates the mounting burden of chronic diseases prompts the demand for robust chronic disease management systems. Furthermore, the expansion of digital health technologies such as remote patient monitoring, electronic health record (EHR)-integrated platforms, and artificial intelligence (AI)-driven predictive analytics boosts the ability to deliver personalized care and enhanced patient outcomes, thus further fueling the market need.
 

Furthermore, growing government support, reimbursement policies, and investment within chronic care programs drives the growth of the market. In addition, the elevated adoption of telehealth solutions propelled since the COVID-19 pandemic has further shifted the industry toward remote care models bolstering the growth within the market in coming years.
 

Chronic disease management refers to an organized approach of monitoring, preventing, and managing long-term health conditions such as diabetes, CVD, hypertension and other chronic diseases. This also includes the implementation of advanced techniques such as telehealth, digital health solutions, remote patient monitoring, EHR integrated systems, and personalized frameworks to improve the outcomes of chronic care.
 

Chronic Disease Management Market Trends

Telehealth solutions, including virtual consultations, remote patient monitoring devices, and data-driven analytics, enable continuous care, improved patient engagement, and better management of chronic conditions fueling the market growth.
 

• The increased accessibility of telehealth technology allows for a decrease in the frequency of in-person visits, supporting rapid access to care, and fosters prompt intervention that strengthens the disease management imperative.
   
• This approach tends to improve the treatment outcome due to the collection of data in real-time, timely interactions, and the tailoring of treatment to the individual patient's needs.
   
• In addition, telehealth technologies extend the regions where healthcare services can be accessed scarcely, particularly in the remote or rural areas that enhances market expansion. The advanced AI and machine learning capabilities further add to market appeal by improving the precision and effectiveness of telehealth in managing chronic conditions.
   
• However, addressing the recent demand for virtual consultations and treatment has compelled industry players to develop new innovations that overcome their challenges while simultaneously contributing to gain traction in the market.
   
• For instance, in March 2023, Royal Philips broaden its telehealth service offering with the introduction of Philips Virtual Care Management. It enables health systems, providers, payers, and employer groups to deliver care and engage with their patients remotely. The platform was designed to alleviate staff burden within the hospitals, reducing emergency department visits, and decreasing the healthcare spending through more effective chronic disease management. This advanced telehealth services have led to rapid growth in disease management services.
   
• Thus, the telehealth industry and the management of chronic diseases are steadily growing due to the adoption of remote healthcare approaches that were intensified during the COVID-19 pandemic.
   

Further, the limited healthcare infrastructure in developing regions coupled with the high cost of implementation of disease management solutions expects to impede the adoption of highly sophisticated frameworks. Moreover, security concerns coupled with the hesitance in accepting digital healthcare technologies further limit the market growth.
 

Trump Administration Tariffs

• The Trump administration’s reciprocal tariffs may significantly impact the chronic diseases management market, particularly by increasing the cost and supply chains disruption of medical devices used for managing chronic conditions such as diabetes, heart disease, and others.
   
• Semiconductors and medical-grade materials that are components of medical equipment are imported from China including insulin pumps and remote monitoring devices. The tariffs placed on those imports will considerably increase the production cost.
   
• In addition, major medical devices companies such as Medtronic, Abbott and Boston Scientific may face substantial financial impact due to the increased operational costs and hike prices for end users due to these tariffs.
   
• Although some pharmaceuticals have received exemptions on tariff restrictions, healthcare is yet struggling with the challenges of trade policies in regard to medical equipment.
   

Chronic Disease Management Market Analysis

Based on disease type, the global market is segmented into cardiovascular diseases (CVD), diabetes, chronic respiratory pulmonary diseases (COPD), cancer, neurological disorders, and other disease types. The cardiovascular diseases segment dominated the market and was valued at USD 2.2 billion in 2024 and is poised to reach USD 6.3 billion by 2034.
 

• The growing CVD cases impacting the economic burden reinforced the demand for effective CVD management solutions.
   
• Chronic CVD conditions such as hypertension, coronary artery disease and heart failure are severe conditions necessitating the continuous monitoring and long-term care.
   
• For instance, according to the Global Burden of Disease (GBD) special report published in JACC reported that global deaths due to CVD rose from 12.4 million in 1990 to 19.8 million in 2022. This increase reflected global population growth, aging, and the impact of preventable risk factors such as metabolic, environmental, and behavioral conditions. Thus, the rise in CVD prevalence highlighted the growing need for advanced chronic disease management solutions, particularly in monitoring and early detection, that expect to contribute to reducing mortality rates and improving patient outcomes.
   
• Further, the need for early diagnosis, personalized treatment, and sustained patient interaction has accelerated the adoption of digital health tools and telehealth services. These advanced monitoring technologies such as wearable devices and remote patient monitoring systems play a crucial role in tracking vital signs like blood pressure, heart rate, and cholesterol levels intended to improve the patient outcome thereby driving the market growth.
   
• Moreover, increasing concern about CVD alongside supportive government policies aimed at decreasing mortality associated with heart diseases has further accelerated growth.
   
• Therefore, the aforementioned factors are anticipated to expand the demand for disease management solutions, reinforcing the CVD segment’s dominance in the market.
   

Based on the type, the global chronic disease management market is categorized into solutions and services. The solutions segment leads the market generating the revenue of USD 4.2 billion in 2024 and is projected to grow at a CAGR of 12.1% to reach USD 13.1 billion by 2034.
 

• The solutions segment prominence was driven due to the growing demand for comprehensive technology driven solutions facilitating real-time disease monitoring and patient engagement.
   
• The solutions segment is further classified into web-based solutions, cloud-based solutions, and on-premises solutions. The cloud-based solutions gained traction due to their scalability, cost-effectiveness, and seamless integration capabilities.
   
• These solutions manage to improve patient care coordination and enhance outcomes for chronic conditions such as diabetes and CVD.
   
• In addition, the healthcare providers inclining towards these digital solutions to improve care coordination, decrease hospital re-admissions, and enhance clinical outcomes has gained traction in the market.
   
• Further, the advances in AI, cloud computing, and data analytic disciplines have enhanced the accuracy and efficiency of these solutions, making them indispensable in healthcare systems. They are leaders in proactive care as well as patient-centered care, thus the solutions segment leads in growth.
   
• Moreover, the growth further driven by rising healthcare investments, the shift towards value-based care, and the growing need for cost-effective chronic disease management solutions.

Based on the end use, the global chronic disease management market is categorized by providers, payers, and other end users. The providers segment dominated the market in 2024 accounting for 53.8% share in the market and is anticipated to reach USD 9.9 billion by 2034 at a CAGR of 11.5%.
 

• The providers segment dominance was driven due to their comprehensive care offering with continuous follow-up of patients with enduring health issues and ongoing clinical consultation.
   
• Healthcare providers including hospitals, clinics, and specialized care centers play a central role in utilizing advanced disease management solutions for tracking their patient’s progress, modifying treatment plans as needed, and mitigating complications.
   
• The growing burden of healthcare conditions such as diabetes, CVD, and asthma has compelled the provider in adopting digital health technologies, telehealth services, and remote monitoring systems to improve care delivery.
   
• In addition, the timely interventions, continuous monitoring intends access by these providers enhance the patients compliance with prescribed treatment regimens.
   
• Thus, the integrated health systems utilizing technology for remote monitoring, optimizing patient care processes, outcomes, and long-term disease management collectively solidified the provider’s position in the global market.

In 2024, U.S. chronic disease management market accounted for USD 2.2 billion revenue from USD 2 billion in 2023 and is anticipated to grow at a CAGR of 11.1% between the 2025 to 2034 period.
 

• The U.S. stand as a leader in the North American market due to its advanced healthcare infrastructure, high chronic disease burden and wide adoption of advanced digital health technologies for disease management.
   
• The increasing prevalence of diabetes, heart disease, and COPD among the population necessitates the need for efficient and scalable management solutions. The U.S. has an advantage because of the widespread use of telehealth and chronic care remotely monitored devices, and EHRs that tend to improve remote chronic care delivery.
   
• For instance, according to the American Public Health Association, over 29 million U.S. adults had three or more chronic conditions in 2022. However, according to the research studies and World Health Organization (WHO), hypertension is the second most leading chronic disease in U.S. As hypertension affects about one in three individuals and significantly leads to chronic conditions such as heart disease and kidney failure. This severity necessitated the need for effective treatment management solutions.
   
• In addition, the market has been further stimulated by telehealth adoption, positive reimbursement policies, investments in healthcare IT, and government spending in the sector.
   
• Moreover, the collaborative strategies among the healthcare providers and key players to continuously provide better managed care services at a lower cost has further strengthen the industry growth in U.S.
   

Germany shows strong growth potential in the Europe chronic disease management market.
 

• Germany demonstrated robust growth potential leveraging its well-developed healthcare system, aging demographics, and increasing prevalence of chronic disorders such as diabetes, CVD, and respiratory diseases.
   
• The country's proactive approach towards digital health including the adoption of EHR and telemedicine enables efficient monitoring and management of chronic diseases. For instance, the Digital Healthcare Act, passed in November 2019, authorizes healthcare providers in Germany to prescribe digital health applications (DiGA) promoting the integration of telehealth, EHR and other digital health tools. This initiative aimed to support the advancements for disease management and care in the country.
   
• Furthermore, the strong focus on research and development, coupled with the use of AI technologies in health, improves the monitoring and tailoring of services provided to the patients.
   
• With the sustained growth of healthcare expenditure and the enhanced collaboration between international and local business stakeholders, Germany is expected to maintain a prominent position in the European market.
   

China chronic disease management market in Asia Pacific is poised to grow at a significant growth rate over the next few years.
 

• China’s substantial growth was driven due to the large aging population coupled with the elevated prevalence of chronic conditions such as diabetes, CVD, among others.
   
• Urbanization and lifestyle changes have intensified the prevalence of diabetes, CVD and cancer prompting the need for long-term care solutions.
   
• For instance, diabetes currently afflicts more than 118 million people in China, making it the leading population of diabetes in the world according to the IDF Diabetes Atlas. Their estimate suggests this number constitutes around 22% share of global diabetes prevalence. Along with the world’s increasing diabetes population, the advancement of technology is required for the management of chronic diseases like cardiovascular conditions.
   
• Moreover, the China government's policies directed towards healthcare reform alongside digital health initiatives, facilitates further growth within the country. This is exemplified by the Healthy China 2030 plan which seeks the enhancement of the prevention and management of chronic diseases to sustain the market growth.
   
• In addition, the improved access to care services driven by the expanded access telemedicine, remote monitoring technologies, mhealth, and the apps in China has optimized healthcare access to rural and underserved regions.
   
• Therefore, the aforementioned factors have reinforced China as one of the foremost contributors to development in the chronic disease management sector in the Asia Pacific region.
   

Brazil is projected to witness significant growth in Latin America chronic disease management market in coming years.
 

• Brazil's substantial growth was signified to the soaring prevalence of diabetes and its comorbidities such as CVD and chronic respiratory diseases.
   
• The increasing adoption of digital health technologies, including cloud and web-based disease monitoring systems, as well as patient engagement frameworks, continue to foster remote monitoring and enhanced healthcare interactions within the country.
   
• Further, the increased government spending towards integrating telehealth services and disease preventive measures also widen the scope of maintenance within the region.
   
• Moreover, the growing investment by the industry players to enhance the business penetration in the country fuels the market expansion. With accelerated investment focus alongside emerging care tailoring technologies, Brazil stands to lead the region in chronic illness management innovation.
   

Saudi Arabia is anticipated to grow in the Middle East and African chronic disease management market.
 

• The growing country’s investment in the digital health industry enabled the growth to be driven by the constant rise in prevalence of chronic diseases.
   
• In addition, the growing government support and industry players efforts focusing on digitizing healthcare through programs like the Vision 2030 initiative, fueling investment in telehealth, EHR systems and remote monitoring for better chronic disease management.
   
• Similarly, in May 2023, King Faisal Specialist Hospital and Research Centre (KFSH&RC) launched the Strategic Partner in Innovation & Excellence (SPInE) to enhance the prospects of healthcare and AI in Saudi Arabia and beyond. The initiative aims to create a comprehensive and flexible framework that merges data, automated algorithms, and resources that advances the use of AI in diagnostic imaging, genomics, preventive medicine, and epidemiology and foster interdisciplinary collaboration between healthcare professionals, researchers, and technologists.
   
• Furthermore, the growing infrastructure alongside an increase in public healthcare awareness and the county’s further burgeoning elderly population, signified Saudi Arabia as a leading market prospective within the region.
   

Chronic Disease Management Market Share

The top five players in the global market accounted for nearly 40% of the market share. Leading companies such as IBM, Epic Systems, Oracle, Veradigm and Teladoc offer comprehensive digital health solutions and services that combine EHR telehealth services, and predictive analytics for improving patient outcomes mitigating to the chronic disease management. While the emerging players specialize in digital therapeutics and personalized care programs.
 

Furthermore, the growing adoption of mHealth solutions providing patients with real-time access to essential information and assistance improves patient outcomes while simultaneously lowering the overall cost of healthcare. Thus, the competitive landscape is shaped by technological advancements, patient-centric approaches, increasing investments, fostering market growth and diversification.
 

Chronic Disease Management Market Companies

Few of the prominent players operating in the chronic disease management industry include:

• Active Health Technologies
• Amwell
• Apollo TeleHealth
• Epic Systems
• HealthSnap
• IBM
• Koninklijke Philips N.V.
• Medicross
• Medtronic
• Oracle
• ResMed
• ScienceSoft USA
• Teladoc
• TimeDoc Health
• Topcon Healthcare
• Veradigm
• ZEISS
   
• Epic Systems offer cutting-edge solution MyChart, an integrated EHR system that allows for real-time patient engagement and facilitates interdisciplinary chronic care collaboration. Its interoperability with other health systems promotes data interchange, enhancing information continuity and longitudinal disease management as well as personalized care outcomes.
   
• IBM leverages an AI-powered Watson Health platform that brings predictive analytics and decision support services for chronic disease management. Its integrity lies in large-scale data insight with clinical workflows, thus facilitating advanced technology for early detection, risk stratification, and tailored treatment paradigms.
   
• Veradigm provides data-based solutions incorporating EHRs, analytics, and provider-payer connections. Its platforms improve real world evidence generation, clinical decision support, and care coordination enabling providers to manage chronic conditions more efficiently across multiple care settings.
   

Chronic Disease Management Industry News

• In April 2025, Lillia, an AI startup, developed a platform for managing diabetes and other chronic conditions using AI technology and human expert training. For their digital twin technology, they have secured a USD 1.7 million grant from QRDI Council, which aims to transform chronic care through real-time predictive interventions. This innovation marks progress in the disease management solution which enhances the virtual consultation experience.
   
• In January 2024, Amazon Health initiated a “Health Condition Programs,” enabling customers to access digital health benefits aimed at managing chronic conditions such as pre-diabetes, diabetes, and hypertension. This was aimed particularly at accessibility as a form of technology-enabled healthcare with improved management result outcomes.
   
• In March 2023, Amwell embedded DarioHealth's digital therapeutic solution into its new cardiometabolic program which aims to care for patients with chronic diseases such as diabetes and hypertension. This partnership sought to enhance Amwell’s capabilities while fueling innovation in the market.
   

The chronic disease management market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Cardiovascular diseases (CVD)
• Diabetes
• Chronic respiratory pulmonary diseases (COPD)
• Cancer
• Neurological disorders
• Other disease types

Market, By Type

• Solutions
  • Web-based solutions
  • Cloud-based solutions
  • On-premises solutions
• Services
  • Disease management program and services
  • Monitoring services
  • Counseling and support services
  • Other service types

Market, By End Use

• Providers
• Payers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE